EKSO - Ekso Bionics Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Ekso Bionics Holdings, Inc.

1414 Harbour Way South
Suite 1201
Richmond, CA 94804
United States
510-984-1761
http://www.eksobionics.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven A. ShermanExec. Chairman93.7kN/A1946
Mr. Jack PeurachPres, CEO & Director334.63kN/A1966
Mr. John F. GlennCFO & Sec.155.24kN/A1962
Mr. William R. ShawChief Commercial OfficerN/AN/A1974
Ms. Foon Lim ChweePres of APACN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company's Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.

Corporate Governance

Ekso Bionics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.